Literature DB >> 27237136

Radiosynthesis of [18F]-fluorobenzoate-doxorubicin Using Acylation Approach.

Pardeep Kumar, Ankit Watts, Pratap Acharya, Ranju Bansal, Anchal Ghai, Amritjyot Kaur, Baljinder Singh1.   

Abstract

BACKGROUND: Previously, we have labeled doxorubicin with [99Tc] and evaluated its potential as a SPECT agent to detect cancer in tumor bearing mice. In this study, we sought to radiolabel doxorubicin with [18F] using acylation method.
METHODS: A quaternary salt of the precursor pentamethylbenzyl-4-(trimethylammonium trifluoromethanesulfonate) benzoate was synthesized and characterized by 1H-NMR. As a first step, 4-[18F]- fluorobenzoic acid (FBA) was synthesized from precursor. In second step, [18F]-FBA was further converted to its corresponding acyl form to radiolabel doxorubicin via acylation reaction.
RESULTS: The total reaction time for the synthesis of [18F]-fluorobenzoate-doxorubicin was about 60 minutes. The radiolabeling efficiency of the final product was estimated to be about 59.0% The radiochemical yield for the synthesis of [18F]-FBA and [18F]-fluorobenzoate-doxorubicin were 19.0- 29.0% and 12.0-14.0% respectively.
CONCLUSION: Radio synthesis of [18F]-fluorobenzoate-doxorubicin by acylation is a convenient method. However, further improvement in the labeling strategy is required to increase the radiolabeling efficiency and radio synthesis yield. Also, the radiolabeled product needs a detailed pre-clinical evaluation. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Acylation; PET; doxorubicin; fluorine-18; radiolabeling; radiosynthesis.

Mesh:

Substances:

Year:  2016        PMID: 27237136     DOI: 10.2174/1874471009666160530152015

Source DB:  PubMed          Journal:  Curr Radiopharm        ISSN: 1874-4710


  1 in total

1.  Evaluating Radioactive Analogs of Doxorubicin to Quantify ChemoFilter Binding and Whole-Body Positron Emission Tomography/Magnetic Resonance Imaging for Drug Biodistribution.

Authors:  Parth Kumar; Colin Yee; Joseph E Blecha; Thomas R Hayes; Bridget F Kilbride; Carol Stillson; Aaron D Losey; Eric Mastria; Caroline D Jordan; Tony L Huynh; Terilyn Moore; Mark W Wilson; Henry F VanBrocklin; Steven W Hetts
Journal:  J Vasc Interv Radiol       Date:  2022-03-15       Impact factor: 3.682

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.